Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive.
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' narrative. UnitedHealth Group is charging patients a markup for key life-saving drugs that could easily exceed their cost by a factor of ten or more,
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months critical of pharmacy benefit managers.
The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was overcharging cancer patients by 1000%.
A bill filed Thursday (Jan. 16) in the Arkansas Legislature would prohibit pharmacy benefit managers and insurance companies from obtaining retail permits and operating pharmacies and mail order services
In the report, the FTC said pharmacy benefit managers (PBMs), charge significant markups for cancer, HIV, and other critical specialty generic drugs, marking up the prices of drugs by hundreds and thousands of percent, bringing in an additional $7.3 billion in revenue.